"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 3 | 6 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 8 | 9 |
| 2001 | 7 | 2 | 9 |
| 2002 | 5 | 6 | 11 |
| 2003 | 7 | 6 | 13 |
| 2004 | 8 | 5 | 13 |
| 2005 | 8 | 6 | 14 |
| 2006 | 5 | 9 | 14 |
| 2007 | 9 | 4 | 13 |
| 2008 | 8 | 2 | 10 |
| 2009 | 12 | 9 | 21 |
| 2010 | 11 | 4 | 15 |
| 2011 | 14 | 11 | 25 |
| 2012 | 8 | 6 | 14 |
| 2013 | 9 | 4 | 13 |
| 2014 | 13 | 3 | 16 |
| 2015 | 22 | 8 | 30 |
| 2016 | 9 | 12 | 21 |
| 2017 | 24 | 9 | 33 |
| 2018 | 22 | 6 | 28 |
| 2019 | 19 | 9 | 28 |
| 2020 | 17 | 16 | 33 |
| 2021 | 17 | 15 | 32 |
| 2022 | 5 | 30 | 35 |
| 2023 | 6 | 26 | 32 |
| 2024 | 12 | 7 | 19 |
| 2025 | 20 | 3 | 23 |
| 2026 | 14 | 3 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Multinational Retrospective Chart Review of Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Solid Organ Transplant Recipients With Refractory/Resistant Cytomegalovirus Infection or Intolerance to Anti-Cytomegalovirus Therapy. Transplant Proc. 2026 Oct; 58(8):1653-1669.
-
A Label-Free, Real-Time Impedance-Based Method for High-Throughput Antiviral Screening. J Vis Exp. 2026 09 03; (235).
-
What's Old Is New Again: Varicella. Pediatrics. 2026 Sep 01; 158(3).
-
Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA Pediatr. 2026 Sep 01; 180(9):951-960.
-
A small molecule inhibits Ebola virus entry through glycoprotein stabilization. Nat Commun. 2026 09 01; 17(1).
-
ICU admission and mortality in adult patients with influenza A(H1N1)pdm09-related pneumonia in Vietnam since the 2009 H1N1 pandemic: A 10-year cohort study. PLoS One. 2026; 21(8):e0348450.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i18-i23.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i1-i17.
-
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial. Clin Infect Dis. 2026 07 23; 83(1):59-69.
-
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions. Liver Int. 2026 07; 46(7):e70734.